This page describes published research and public regulatory records. It is not medical advice. SoluneFit does not sell, supply, or recommend any compound. The SoluneFit app includes a private, on-device tracker for people who want a record of what they and their clinician have already decided — the app neither suggests compounds nor doses.
Also known as: EDR peptide, Glu-Asp-Arg, Пинеалон.
Regulatory status
Not FDA-approved; no IND and no ClinicalTrials.gov record. Not on any of FDA's 503A bulk-substance category lists (14 May 2026) and not among the seven peptides reviewed at the July 2026 PCAC meeting, so it has no standing for US pharmacy compounding [5][6]. In Russia it is listed as a dietary supplement (БАД, oral capsules and tablets), not a registered medicine [8].
What it is
Synthetic tripeptide (Glu-Asp-Arg), one of the Khavinson 'peptide bioregulators'.
A three-amino-acid peptide from Vladimir Khavinson's St Petersburg Institute of Bioregulation and Gerontology, promoted there as a brain-protective 'geroprotector'. Nearly all published work comes from that group or Russian collaborators, mostly in cells and rats.
What the published research shows
Mostly cell-culture and rat studies from one research group. Human data are small, uncontrolled Russian reports known only from abstracts or the group's own summaries (e.g. 72 patients after brain injury on oral pinealon, design not described; one uncontrolled 32-person study with a second peptide). Nothing controlled or independently replicated; bottom of grade C.
Published human studies and reports (these describe trial populations, not SoluneFit claims):
- Cell culture (Khavinson et al., Rejuvenation Res 2011): In rat cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, pinealon reduced reactive-oxygen-species build-up and necrotic cell death in a dose-dependent way.
- Rat offspring (Arutjunyan et al., Int J Clin Exp Med 2012): Rat study reporting protection of offspring from prenatal hyperhomocysteinaemia.
- Older adults with organic brain syndrome (Meshchaninov et al., Adv Gerontol 2015, in Russian): 32 people aged 41–83 given pinealon or vesugen, uncontrolled; authors reported improvements in 'biological age' markers, and also a pro-oxidant effect and a fall in CD34+ blood stem-cell markers.
- After traumatic brain injury (as summarised in Khavinson et al., Molecules 2020): Review reports oral pinealon added to standard therapy in 72 patients with improved memory and less headache; dose, duration and control group are not given.
- Mechanism review (Khavinson et al., Molecules 2020): Review by the originating group of proposed gene-expression effects relevant to Alzheimer's disease, drawn from in-vitro and animal work.
Mechanism, as reported
Not established. The originating group proposes that the tripeptide enters cells and nuclei and binds DNA or histones to change gene expression, and reports antioxidant effects in cell culture; neither has been independently confirmed.
Practical record
- Studied routes: oral.
- Typical supply: Russia: dietary-supplement capsules (0.2 g) and tablets (0.16 g, 0.3 g), peptide content per unit not stated in the registry entry [8]. Elsewhere sold on the research-chemical market (unregulated).
Safety signals on record
- Reported adverse events: Not established: no systematic safety data in humans. The one uncontrolled human report described a pro-oxidant effect and reduced CD34+ blood stem-cell markers (read by its authors as reduced blood-cell production).
- Contraindications: None established (no label).
- Interactions: None documented.
- Notes: Evidence base comes almost entirely from the group that developed and promotes it; no independent replication. Human doses are not reported in the sources found. WADA S0 prohibits substances with no governmental approval for human therapeutic use [7].
Sources
- Khavinson V et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res 2011;14:535-541 (2011)
- Arutjunyan A et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med 2012;5:179-185 (2012)
- Meshchaninov VN et al. [Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]. Adv Gerontol 2015;28:62-67 (Russian) (2015)
- Khavinson V et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules 2020;26:159 (2020)
- FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (categories 1–3), updated 14 May 2026 (2026)
- FDA: July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (meeting page) (2026)
- World Anti-Doping Agency. Prohibited List 2026, S0 Non-approved substances (2026)
- RLS (Register of Medicines of Russia): Пинеалон — registration data for a dietary supplement (БАД), capsules 0.2 g / tablets 0.16 g and 0.3 g (2022)
General wellness education, not medical advice. Unapproved compounds have no established dosing, purity standard, or safety profile.